Aesthetic · Research reference

PT-141 10mg

Bremelanotide — α-MSH analog. Cyclic α-melanocyte-stimulating hormone analog. Researched for melanocortin-4 receptor activation pathway modeling.

See the wiki entry

Half-life

~2 hours (SC)

Molar mass

1025.18 g/mol

Purity floor

≥99%

CAS

189691-06-3

Mechanism

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin-receptor agonist. In vitro it activates MC3R and MC4R subtypes with nanomolar affinity.

Common in-vitro applications

Melanocortin receptor signaling
cAMP assays in HEK293 cells expressing recombinant MC3R / MC4R.
Working range: nM range
Receptor selectivity profiling
Comparative binding panels across MC1R–MC5R subtypes.
Working range: nM range

Reconstitution + storage

Reconstitution

2ml bacteriostatic water → 5mg/ml

Per-vial mass

10mg

Lyophilized storage

−20°C or below, desiccated

Reconstituted storage

2–8°C, use within 30 days

Light + air

Protect from light and air

Solubility

Soluble in bacteriostatic water (0.9% benzyl alcohol)

Background: lyophilization · reconstitution

Co-treatment partners

Melanotan-II
Non-selective melanocortin agonist comparator.

Selected peer-reviewed citations

Molinoff PB, et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences.

Verification

Read the COA

Open the batch lookup — Janoshik HPLC-UV + ESI-MS packet.

Open

Buy this kit

PT-141 10mg · $60

Lyophilized, COA-verified, tracked US shipping.

Open the PDP

Reference data is supplied for in-vitro literature context only. Aurex does not provide dosage or use guidance — Federal regulations governing research-chemical distribution prohibit it. PT-141 10mg is sold for in-vitro research applications only, by qualified researchers. Not for human or veterinary use. Not FDA approved.

All peptides